Savient Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 72   

Articles published

SVNTQ 0.0019
price chart
Bridgewater-based Savient Pharmaceuticals OKd for Chapter 11 plan
Savient Pharmaceuticals Inc., a developer of a treatment for gout before its business was sold, got approval of a liquidating Chapter 11 plan, with U.S.
Savient Pharmaceuticals files for Chapter 11 bankruptcy
U.S. biotech firm Savient Pharmaceuticals Inc filed for Chapter 11 bankruptcy protection in a Delaware court on Monday and said it has agreed to sell most of its assets to Sloan Holdings CV for about $55 million.
Savient Pharmaceuticals Files for Bankruptcy  Bloomberg
Savient Pharmaceuticals Commences Voluntary Chapter 11 Proceeding; Seeks ...  PR Newswire (press release)
Related articles »  
Savient Pharmaceuticals Announces Formation of Office of the President
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA (pegloticase) for the treatment of chronic gout in adult patients who do not respond to conventional therapy.
Related articles »  
DEADLINE ALERT: Rigrodsky & Long, PA Reminds Shareholders Of Savient ...
Rigrodsky & Long, P.A., including former Special Assistant United States Attorney, Timothy J. MacFall, reminds shareholders of Savient Pharmaceuticals, Inc. (“Savient” or the “Company”) (OTC QB: SVNTQ) of an upcoming deadline involving a securities ...
Related articles »  
Savient Pharmaceuticals, Inc. (SVNT): Are Hedge Funds Right About This Stock?
When looking at the hedgies we track, William Leland Edwards's Palo Alto Investors had the most valuable position in Savient Pharmaceuticals, Inc. (NASDAQ:SVNT), worth close to $11.8 million, accounting for 1.4% of its total 13F portfolio. Coming in ...
Related articles »  
Savient Pharma Unveils Ch. 11 Plan
Law360, New York (February 10, 2014, 7:01 PM ET) -- Drug developer Savient Pharmaceuticals Inc. unveiled its Chapter 11 plans in Delaware bankruptcy court Monday, calling for the liquidation of its U.S.
Related articles »  
Savient Pharmaceuticals: Value Play Or Value Trap?
Savient Pharmaceuticals, Inc. (SVNT), based in East Brunswick, NJ is a biotechnology company engaged in the commercialization of Krystexxa (first and only in its class), for refractory chronic gout (RCG), an indication for which SVNT has obtained ...
Trying to Get a Handle on Savient Pharmaceuticals' Valuation
It is the same company that was selling for $22/share a few days ago. There have been no accounting irregularities. No new problems with the drug have been discovered.
Savient's Auction Didn't Result in Sale, Company Says  Bloomberg
Savient Pharmaceuticals: Is Anything Left?
This is hardly enough to sustain the company, and it took a loss of $28.0 million for that quarter. With SVNT's current cash cushion of $96.3 million, it is clear that Savient will have to turn something around, and fast. Its prescription rates for ...
Savient Pharmaceuticals, Inc. v. Tang Capital Partners, LP, et al., C.A. No ...
Plaintiffs are note holders of Savient Pharmaceuticals, Inc. (“Savient” or the “Company”), whose principal asset is the worldwide ownership and license rights of the drug KRYSTEXXA.